
    
      This is an open-label Phase 1 dose escalation and expansion study of OMP-305B83 in subjects
      with previously treated solid tumors. Study includes a dose escalation phase and expansion
      phase. Subjects will be assessed for safety, immunogenicity, pharmacokinetics, biomarkers,
      and efficacy.
    
  